- €797.12m
- €743.62m
- €19.52m
Brief: Medincell Reports H1 Net Loss Of 10.8 Million Euros
Brief: Medincell Initiates First Clinical Trial Of Its Covid-19 Prevention Program
Brief: Medincell Raises EUR 15.6 Million In Capital Increase
Brief: Medincell Launches Capital Increase Of 11 Millions Euros
Brief: Euronext announces quarterly revision of French indices
Brief: Medincell FY Operating Loss Widens To 19.3 Million Euros
Brief: Medincell Secures Non-Dilutive Financing Of 10.9 Million Euros
Brief: Medincell: Product Portfolio Progresses Well Amid COVID-19 Pandemic
Brief: Medincell Launches Regulatory Development Of Mdc-WWM Program
Brief: MedinCell Receives $6.4 Million Grant From Unitaid To Fight Malaria
Brief: Us Pharma Development Veteran Dr. Richard Malamut Joins The Medical Advisory Board Of Medincell
Brief: MedinCell End-Sept Operating Loss Widens To EUR 8.1 Million
Brief: Medincell Receives $19 Million Grant For Its Mdc-WWM Program
Brief: Medincell Receives Grant For Product Aimed At Preventing HIV infection
Brief: Medincell Partners With Cornerstone Animal Health
Brief: Long-Acting Injectable Antipsychotic Using Medincell’s Technology Receives FDA IND Clearance To Initiate Clinical Activities
Brief: MedinCell Receives 7,5 Million Euros From The EIB
Brief: Medincell: Preclinical Studies On Long-Acting Injectable MDC-ANG To Start This Quarter
Brief: Medincell FY Operating Loss Widens To 15.5 Million Euros